Comment from Northwest Biotherapeutics

Summary: Northwest Biotherapeutics, a clinical-stage biotechnology company, supports the draft guidance but requests specific language changes to broaden its scope. They argue that the framework should explicitly include cancer and cell therapies, as well as "cellular or molecular conditions," to ensure regulatory fairness across different treatment modalities.